Qiagen (QGEN)

• Market cap: $9.15B
• 1 day: -1.76%
• 5 days: -0.49%
• 1 month: 2.24%
• 3 months: -13.95%
• 6 months: -7.29%
• Year to date: -11.09%
• 1 year: 0.89%
• 5 years: -5.35%
• 10 years: 47.02%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Employees: 5,765

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $52.2M | Put options by funds: $35.2M

8% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 107

4% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 51

4% less capital invested

Capital invested by funds: $6.85B [Q3] → $6.58B (-$273M) [Q4]

2% less funds holding

Funds holding: 325 [Q3] → 319 (-6) [Q4]

2.02% less ownership

Funds ownership: 68.28% [Q3] → 66.27% (-2.02%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 3% upside
• Avg. target: $45 11% upside
• High target: $48 18% upside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target	3% upside $42	Neutral Downgraded	19 Feb 2025
UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target	18% upside $48	Neutral Maintained	7 Feb 2025